Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3alpha-reduced neurosteroids

• Published in: Pain (Amsterdam) Vol. 147; no. 1-3; pp. 54 - 59
• Main Authors: Aouad, Maya, Charlet, Alexandre, Rodeau, Jean-Luc, Poisbeau, Pierrick
• Format: Journal Article
• Language: English
• Published: United States 15.12.2009
• Subjects: Analysis of Variance; Animals; Anti-Anxiety Agents - pharmacology; Anti-Anxiety Agents - therapeutic use; Chi-Square Distribution; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors - pharmacology; Hyperalgesia - chemically induced; Hyperalgesia - physiopathology; Hyperalgesia - prevention & control; Medroxyprogesterone Acetate - pharmacology; Neurotransmitter Agents - metabolism; Oxazines - pharmacology; Oxazines - therapeutic use; Pain Measurement - methods; Pain Threshold - drug effects; Pain Threshold - physiology; Physical Stimulation - adverse effects; Rats; Rats, Sprague-Dawley; Reaction Time - drug effects; Time Factors; Vincristine

The central processing of peripheral nociceptive messages is highly controlled by the activity of local inhibitory networks in the spinal cord and supraspinal centers. Recently, it has been shown that endogenous 3alpha-reduced neurosteroids (3alphaNS) exert a significant spinal antinociception by po...